Aliases & Classifications for Pyoderma

MalaCards integrated aliases for Pyoderma:

Name: Pyoderma 12 54 44 15 70 32

Classifications:



External Ids:

Disease Ontology 12 DOID:4223
ICD9CM 34 686.0
MeSH 44 D011711
SNOMED-CT 67 267838007
ICD10 32 L08.0
UMLS 70 C0034212

Summaries for Pyoderma

Disease Ontology : 12 A dermatitis that is characterized by a pyogenic infection causing the formation of pus.

MalaCards based summary : Pyoderma is related to pyogenic sterile arthritis, pyoderma gangrenosum, and acne and impetigo, and has symptoms including pruritus, exanthema and pustular rash. An important gene associated with Pyoderma is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways/superpathways are Integrin Pathway and Cytokine Signaling in Immune system. The drugs Adalimumab and Antirheumatic Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and myeloid, and related phenotypes are immune system and integument

Related Diseases for Pyoderma

Diseases related to Pyoderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 795)
# Related Disease Score Top Affiliating Genes
1 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 33.0 SIGLEC5 PSTPIP1 MEFV
2 impetigo 31.6 MYOM2 DSG1 CCR6
3 ulcerative colitis 31.3 TNF NOD2 IL1R1 CXCL8 CCR6
4 colitis 31.3 TNF NOD2 IL1R1 CXCL8 CCR6
5 hidradenitis 31.2 TNF NOD2 MEFV
6 acne 31.2 TNF PSTPIP1 ITGB2 IFNA2 CXCL8
7 vasculitis 31.1 TNF MEFV ITGB2 IFNA2 APOH
8 crohn's disease 31.1 TNF NOD2 MEFV CXCL8 CCR6
9 hidradenitis suppurativa 31.1 TNF NOD2 MEFV
10 erythema nodosum 31.0 TNF NOD2 CXCL8
11 pyoderma gangrenosum 30.8 TNF SIGLEC5 PSTPIP1 NOD2 MMP9 MMP26
12 crohn's colitis 30.8 TNF NOD2 CXCL8 CCR6
13 fasciitis 30.8 TNF MYOM2 MMP1 CXCL8
14 chronic recurrent multifocal osteomyelitis 30.7 TNF PSTPIP1 MEFV
15 osteomyelitis 30.7 TNF NOD2 MEFV CXCL8 CSF3
16 panniculitis 30.7 TNF CSF3 BTK
17 myelofibrosis 30.7 TNF IFNA2 CXCL8 CSF3
18 scabies 30.7 CXCL8 CSF3 CCR6
19 erythema elevatum diutinum 30.6 PSTPIP1 CXCL8
20 skin disease 30.6 TNF SIGLEC5 MMP1 ITGB2 DSG1 CXCL8
21 pustulosis of palm and sole 30.6 TNF SIGLEC5 PSTPIP1 CXCL8 CCR6
22 pharyngitis 30.5 TNF MYOM2 MEFV CXCL8
23 purpura 30.5 TNF MEFV F3 APOH
24 diverticulitis 30.5 TNF MMP9 CCR6
25 pouchitis 30.5 TNF NOD2
26 scleritis 30.4 TNF MMP9 ITGB2 CCR6
27 antiphospholipid syndrome 30.4 TNF F3 APOH
28 psoriasis 30.4 TNF NOD2 ITGB2 IL1R1 CXCL8 CCR6
29 collagenous colitis 30.4 NOD2 MMP9 MMP1
30 keratitis, hereditary 30.4 TNF MMP9 CXCL8 CCR6
31 spondylitis 30.4 TNF NOD2 CCR6
32 erysipelas 30.4 TNF MYOM2 MEFV
33 sapho syndrome 30.4 SIGLEC5 NOD2 CXCL8
34 rosacea 30.4 TNF MMP9 CXCL8 CCR6
35 monoclonal gammopathy of uncertain significance 30.4 TNF MYOM2 CCR6
36 disease by infectious agent 30.4 TNF SIGLEC5 NOD2 CCR6
37 diarrhea 30.4 TNF NOD2 IFNA2 CXCL8 CSF3
38 leukocyte adhesion deficiency, type i 30.4 ITGB2 CXCL8 CSF3 CCR6
39 syphilis 30.3 TNF CCR6 APOH
40 cellulitis 30.3 TNF MYOM2 IL1R1 F3 CSF3 CCR6
41 dermatitis 30.3 TNF NOD2 DSG1 CXCL8 CCR6
42 cholangitis 30.3 TNF NOD2 F3 CXCL8
43 neutropenia 30.3 TNF IFNA2 CXCL8 CSF3 BTK
44 sclerosing cholangitis 30.3 TNF NOD2 CXCL8
45 fungal infectious disease 30.3 TNF CXCL8 CSF3 CCR6
46 spondyloarthropathy 1 30.3 TNF NOD2 IL1R1 CCR6
47 exanthem 30.3 TNF MEFV F3 CXCL8 CSF3 CCR6
48 brucellosis 30.3 TNF MEFV CXCL8
49 pericarditis 30.3 TNF MEFV CXCL8
50 cryoglobulinemia 30.3 TNF IFNA2 APOH

Comorbidity relations with Pyoderma via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Peripheral Vascular Disease

Graphical network of the top 20 diseases related to Pyoderma:



Diseases related to Pyoderma

Symptoms & Phenotypes for Pyoderma

UMLS symptoms related to Pyoderma:


pruritus; exanthema; pustular rash

MGI Mouse Phenotypes related to Pyoderma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.77 BTK CCR6 CSF3 F3 IL1R1 ITGB2
2 integument MP:0010771 9.32 BTK CSF3 DSG1 F3 IL1R1 ITGB2

Drugs & Therapeutics for Pyoderma

Drugs for Pyoderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved, Experimental Phase 3 331731-18-1 16219006
2 Antirheumatic Agents Phase 3
3 Anti-Inflammatory Agents Phase 3
4 Pharmaceutical Solutions Phase 3
5
Ixekizumab Approved, Investigational Phase 2 1143503-69-8
6 Dermatologic Agents Phase 2
7 Antibodies Phase 2
8 Immunoglobulins Phase 2
9 Antibodies, Monoclonal Phase 2
10 Immunologic Factors Phase 2
11
Infliximab Approved 170277-31-3
12
Tyrosine Approved, Investigational, Nutraceutical 60-18-4 6057
13 Gastrointestinal Agents
14 Vaccines

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas Withdrawn NCT00202891 Phase 4 sisomicin
2 A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan Completed NCT03311464 Phase 3 adalimumab
3 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02315417 Phase 3 gevokizumab;Placebo;gevokizumab open-label
4 A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum Terminated NCT02318914 Phase 3 gevokizumab
5 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02326740 Phase 3 gevokizumab;Placebo;gevokizumab open-label
6 An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum Completed NCT01882504 Phase 2 gevokizumab
7 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Completed NCT03137160 Phase 2
8 A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum Completed NCT01302795 Phase 2 Canakinumab
9 A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Completed NCT01965613 Phase 2
10 Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum (Optima) Recruiting NCT03971643 Phase 2 IFX-1
11 Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Active, not recruiting NCT02733094 Phase 1, Phase 2 Secukinumab
12 The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum Not yet recruiting NCT04274166 Phase 2 secukinumab 150 mg (2 injections per dose
13 A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum Terminated NCT03072953 Phase 2 APD334
14 Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Withdrawn NCT00730717 Phase 2 Humira;Humira
15 A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37) Withdrawn NCT00690846 Phase 2 adalimumab
16 Retrospective Multicenter Observational Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum in Patients Diagnosed With This Pathology Between 2000 and 2015 Unknown status NCT03636737
17 Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses Unknown status NCT01952275
18 Tele-dermatology of Skin Cancer: a Randomized Trial Comparing Remote Assessment With Conventional Visits in a Cohort of Local Health Authority Employees in the Province of Bergamo (the Shoot the Mole Study) Completed NCT02902822
19 An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum Completed NCT00791557 Infliximab
20 The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) Part 3: The Incidence of Group A Streptococcal Pharyngitis and the Prevalence of Pyoderma and Scabies in School Children in Fiji, and Establishing Immunologic Correlates of Protection for a J8 Vaccine Completed NCT00284882
21 The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) - Part 4 -The Prevalence of Group A Streptococcal Pyoderma and Scabies in Infants in Fiji Completed NCT00436891
22 The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) Part 1: The Prevalence of Rheumatic Heart Disease, Pyoderma and Scabies in School Children in Fiji Completed NCT00284843
23 East Arnhem Healthy Skin Project: A Regional Collaboration to Reduce Scabies, Skin Sores and Associated Chronic Diseases, Including Rheumatic Fever and Renal Disease, Among Australian Aboriginal Communities Completed NCT00884728
24 Post-marketing Observational Study for Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG) Recruiting NCT04750213
25 A Real World, Observational Registry of Chronic Wounds and Ulcers to Assess Quality of Care, Evidence Based Practice and Outcomes Using Linked Electronic Health Record Data Recruiting NCT02280733
26 Expression of the JAK-STAT Signaling Pathway in Pyoderma Gangrenosum Pathological Biopsy Not yet recruiting NCT04792957

Search NIH Clinical Center for Pyoderma

Cochrane evidence based reviews: pyoderma

Genetic Tests for Pyoderma

Anatomical Context for Pyoderma

MalaCards organs/tissues related to Pyoderma:

40
Skin, Neutrophil, Myeloid, Breast, Spleen, Colon, Thyroid

Publications for Pyoderma

Articles related to Pyoderma:

(show top 50) (show all 4757)
# Title Authors PMID Year
1
De novo mutation in the BTK gene of atypical X-linked agammaglobulinemia in a patient with recurrent pyoderma. 61 54
16729790 2006
2
Prediction of the therapeutic mechanism responsible for the effects of Sophora japonica flower buds on contact dermatitis by network-based pharmacological analysis. 61
33493588 2021
3
Pyoderma gangrenosum solved by ustekinumab therapy. 61
33069432 2021
4
Retraction notice to "Pyoderma gangrenosum in a cesarean section wound in a woman with myelodysplastic syndrome: A case report" [Case Reports in Women's Health 28 (2020) e00253]. 61
33614419 2021
5
[An unusually painful leg ulcer in an 81-year-old patient: an interdisciplinary challenge]. 61
33284357 2021
6
Dermatologic sequelae of breast cancer: From disease, surgery, and radiation. 61
33226140 2021
7
Vulvovaginal pyoderma gangrenosum associated with rituximab use in 2 patients with rheumatoid arthritis. 61
33778138 2021
8
Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population. 61
33608949 2021
9
Newly isolated lytic bacteriophages for Staphylococcus intermedius, structurally and functionally stabilized in a hydroxyethylcellulose gel containing choline geranate: Potential for transdermal permeation in veterinary phage therapy. 61
33440244 2021
10
The use of MATRIDERMⓇ as a single stage salvage procedure to cover exposed dura Mater. 61
33319011 2021
11
Demodectic mange in threatened southern sea otters (Enhydra lutris nereis). 61
33739551 2021
12
[Healing of severe morbus Crohn-related pyoderma gangrenosum after colectomy]. 61
33734075 2021
13
Care and treatment of peristomal gangrenous pyoderma. A study of three cases. 61
33541774 2021
14
Using item response theory (IRT) to improve the efficiency of the Simple Clinical Colitis Activity Index (SCCAI) for patients with ulcerative colitis. 61
33752610 2021
15
Estimating the Odds of Ulcerative Colitis-Associated Pyoderma Gangrenosum: A Population-Based Case-Control Study. 61
33647909 2021
16
A case of myeloperoxidase-antineutrophil cytoplasmic antibody and anticardiolipin antibody-positive pyogenic arthritis, pyoderma gangrenosum, acne and hidradenitis suppurativa (PAPASH) syndrome with colitis. 61
33560194 2021
17
Treatment of pyoderma gangrenosum: A multicenter survey-based study assessing satisfaction and quality of life. 61
33394563 2021
18
Pyoderma gangrenosum associated to the use of cocaine/levamisole. Series of three cases and literature review. 61
33640188 2021
19
Recalcitrant cutaneous pyoderma gangrenosum with pulmonary involvement resolved with treatment of underlying plasma cell dyscrasia. 61
33604440 2021
20
Successful treatment of pyoderma gangrenosum associated with IgA gammopathy with the IL-1 receptor antagonist anakinra. 61
33657262 2021
21
Pyoderma gangrenosum secondary to caesarean section treated with negative pressure wound therapy and skin graft. 61
33559207 2021
22
Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti-myeloma treatment. 61
33751551 2021
23
Pyoderma Gangrenosum: A Retrospective Study of Clinical Charac-teristics, Comorbidities, Response to Treatment and Mortality Related to Prednisone Dose. 61
33686448 2021
24
First case of lenvatinib-induced pyoderma gangrenosum: Possible management with dose reduction. 61
33651422 2021
25
Pyoderma gangrenosum associated with Takayasu's arteritis in a young Caucasian woman and response to biologic therapy with tocilizumab. 61
33598515 2021
26
[Lung involvement of pyoderma gangrenosum: Diagnostic and therapeutic discussion based on a case report and a targeted literature review]. 61
33773848 2021
27
Mycophenolate mofetil as adjunctive therapy to corticosteroids for the treatment of pyoderma gangrenosum: a case series and literature review. 61
33739458 2021
28
The role of negative pressure wound therapy (NPWT) on the treatment of pyoderma gangrenosum: A systematic review and personal experience. 61
33772964 2021
29
Abdominal Pyoderma Gangrenosum, Harbinger of Takayasu Arteritis in an African American Patient. 61
30044262 2021
30
Pyoderma gangrenosum associated with limited cutaneous systemic sclerosis: a rare case with literature review. 61
32676919 2021
31
Efficacy and safety of skin grafting in treatment of vasculitic ulcer and pyoderma gangrenosum-A systematic review. 61
33377584 2021
32
Pyoderma gangrenosum with thymoma and myasthenia gravis: A case report. 61
32920928 2021
33
An unusual triple association: Superficial granulomatous pyoderma, subcorneal pustular dermatosis, IgA multiple myeloma. 61
33245568 2021
34
Pyoderma gangrenosum of the breast revealing contralateral breast carcinoma. 61
33675057 2021
35
Recurrent necrotizing cellulitis, multi-organ autoimmune disease and humoral immunodeficiency due to a novel NFKB1 frameshift mutation. 61
33486103 2021
36
Pyoderma Gangrenosum with an Underlying Leukocyte Adhesion Deficiency Type 1 (LAD-1) and Pregnancy in the Shade of COVID-19 Epidemic: A Patient and Physician Experience. 61
33686591 2021
37
Pyoderma gangrenosum and cobalamin deficiency in systemic lupus erythematosus: a rare but non fortuitous association. 61
33653418 2021
38
Primary breast pyoderma gangrenosum: an uncommon cause of breast ulcer. 61
33511730 2021
39
[Current dermatology guidelines in Germany and Europe : A selection of clinically relevant recommendations]. 61
33666670 2021
40
The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study. 61
33810197 2021
41
Extranodal NK/T cell lymphoma, nasal type, mimicking a bullous pyoderma gangrenosum. 61
33527364 2021
42
Cranial aseptic osteomyelitis associated with pyoderma gangrenosum. 61
33546980 2021
43
Superficial Granulomatous Pyoderma Gangrenosum Involving the Face: A Case Series of Five Patients and a Review of the Literature. 61
33541119 2021
44
An extensive pyoderma gangrenosum mimicking necrotizing fasciitis: An unusual case report. 61
33691271 2021
45
Pyoderma gangrenosum following an unplanned caesarean section: a patient revisited. 61
33619133 2021
46
Pyoderma gangrenosum of the penis. 61
33625348 2021
47
One health approach to genetic relatedness in SCCmec between methicillin-resistant Staphylococcus isolates from companion dogs with pyoderma and their owners. 61
33385887 2021
48
Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum. 61
33490346 2021
49
Infliximab Prophylaxis in Patients With Postoperative Pyoderma Gangrenosum Requiring Surgical Intervention. 61
31714378 2021
50
Pyoderma gangrenosum underrepresentation in non-dermatological literature. 61
31913849 2021

Variations for Pyoderma

Expression for Pyoderma

Search GEO for disease gene expression data for Pyoderma.

Pathways for Pyoderma

Pathways related to Pyoderma according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.32 MMP9 MMP26 MMP10 MMP1 ITGB2 CXCL8
2
Show member pathways
13.24 TNF NOD2 MMP9 MMP1 ITGB2 IL1R1
3
Show member pathways
13.09 TNF SIGLEC5 PSTPIP1 NOD2 MMP9 MMP1
4
Show member pathways
12.62 TNF NOD2 IL1R1 IFNA2 F3 CXCL8
5
Show member pathways
12.23 TNF MMP9 MMP1 CXCL8 CSF3
6 12.15 TNF NOD2 ITGB2 IFNA2
7 11.94 TNF MMP9 IL1R1 CXCL8
8 11.87 TNF IL1R1 CXCL8 BTK
9 11.85 TNF ITGB2 IL1R1 CXCL8
10 11.79 TNF MMP1 ITGB2 CXCL8
11 11.71 TNF MMP9 MMP1 ITGB2 CXCL8
12 11.7 TNF IL1R1 CCR6
13 11.69 TNF PSTPIP1 NOD2 MEFV IFNA2 CXCL8
14 11.67 TNF ITGB2 CXCL8
15 11.65 MMP9 MMP1 CXCL8
16 11.6 TNF ITGB2 CCR6
17
Show member pathways
11.56 TNF MMP9 MMP1 CXCL8
18
Show member pathways
11.55 TNF MMP9 MMP26 MMP10 MMP1
19 11.53 TNF ITGB2 CXCL8
20 11.53 TNF MMP9 CXCL8 CSF3
21 11.49 MMP9 MMP10 MMP1 CXCL8
22 11.44 TNF MMP9 ITGB2
23 11.37 TNF ITGB2 CXCL8 CSF3
24 11.31 TNF IL1R1 CXCL8 CSF3
25 11.27 MMP9 MMP1 CXCL8

GO Terms for Pyoderma

Cellular components related to Pyoderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 TNF MMP9 MMP26 MMP10 MMP1 IL1R1
2 ficolin-1-rich granule membrane GO:0101003 9.33 SIGLEC5 ITGB2 DSG1
3 cell surface GO:0009986 9.17 TNF NOD2 ITGB2 IL1R1 F3 CCR6

Biological processes related to Pyoderma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.95 TNF IL1R1 CXCL8 CSF3 CCR6
2 leukocyte migration GO:0050900 9.83 TNF MMP9 MMP1 ITGB2
3 cellular response to lipopolysaccharide GO:0071222 9.76 TNF NOD2 CXCL8 CSF3
4 calcium-mediated signaling GO:0019722 9.74 CXCL8 CCR6 BTK
5 extracellular matrix disassembly GO:0022617 9.71 MMP9 MMP10 MMP1
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.71 TNF NOD2 ITGB2 BTK
7 positive regulation of interleukin-8 production GO:0032757 9.69 TNF NOD2 F3
8 humoral immune response GO:0006959 9.67 TNF IFNA2 CCR6
9 defense response GO:0006952 9.67 TNF NOD2 IFNA2 CXCL8
10 extracellular matrix organization GO:0030198 9.63 TNF MMP9 MMP26 MMP10 MMP1 ITGB2
11 cellular response to UV-A GO:0071492 9.56 MMP9 MMP1
12 collagen catabolic process GO:0030574 9.56 MMP9 MMP26 MMP10 MMP1
13 inflammatory response GO:0006954 9.5 TNF PSTPIP1 MEFV ITGB2 IL1R1 IFNA2
14 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.48 TNF NOD2
15 cellular extravasation GO:0045123 9.43 TNF ITGB2
16 positive regulation of prostaglandin-E synthase activity GO:2000363 9.32 NOD2 ITGB2
17 cytokine-mediated signaling pathway GO:0019221 9.28 TNF MMP9 MMP1 ITGB2 IL1R1 IFNA2

Molecular functions related to Pyoderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 TNF IFNA2 CXCL8 CSF3
2 metallopeptidase activity GO:0008237 9.26 MMP9 MMP26 MMP10 MMP1
3 metalloendopeptidase activity GO:0004222 8.92 MMP9 MMP26 MMP10 MMP1

Sources for Pyoderma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....